OLIGONUCLEOTIDES FOR DGAT2, FASN, OPN, AND NOX4 MODULATIONS

This disclosure relates to the combination of DGAT2 targeting sequences with FASN, OPN, and/or NOX4 targeting sequences, and methods for treating and preventing non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and lipodystrophy syndromes. La présente invention concern...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YENILMEZ, Batuhan Orbay, KHVOROVA, Anastasia, WATTS, Jonathan Kenneth, CZECH, Michael
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This disclosure relates to the combination of DGAT2 targeting sequences with FASN, OPN, and/or NOX4 targeting sequences, and methods for treating and preventing non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and lipodystrophy syndromes. La présente invention concerne la combinaison de séquences ciblant DGAT2 avec des séquences ciblant FASN, OPN et/ou NOX4, et des méthodes de traitement et de prévention d'une stéatose hépatique non alcoolique (NAFLD), d'une stéatohépatite non alcoolique (NASH) et de syndromes de lipodystrophie.